chronic heart failure

Oral Relaxin Receptor Agonist AZD5462 Shows Promise in Chronic Heart Failure: Insights from the LUMINARA Trial

By MedXY 09/02/2026

The LUMINARA trial evaluates AZD5462, an oral relaxin receptor agonist, demonstrating safety and promising effects on cardiac remodeling and vascular resistance in chronic heart failure, warranting further large-scale investigation.

Cardiology news

Dynamic Metabolic Profiling in Chronic Heart Failure: Insights from Serial NMR Biomarkers and Risk Prediction

By MedXY 08/13/2026

Serial nuclear magnetic resonance metabolic profiling reveals distinct lipid and inflammatory markers predictive of adverse outcomes in chronic heart failure, supporting its role in improving risk stratification.

Cardiology Clinical Updates news

Cellular Adhesion Molecules as Prognostic Biomarkers and Therapeutic Insights in Chronic Heart Failure: Integrative Review Emphasizing DAPA-HF Findings

By MedXY 12/03/2025

Elevated VCAM-1 levels correlate with worse outcomes in chronic HFrEF, independent of conventional markers; dapagliflozin’s benefits are consistent across VCAM-1 levels, highlighting inflammatory pathways as therapeutic targets.

Cardiology Clinical Updates news Respiratory Specialties

Decoding the Link Between Pulmonary Artery Pressures and Mortality in Chronic Heart Failure Patients

By MedXY 08/17/2025

Remote monitoring of systolic, diastolic, and mean pulmonary artery pressures predicts 2-year all-cause mortality in chronic heart failure across ejection fraction categories, informing personalized management strategies.